SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration - neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other devastating CNS diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/04/25 | $53,000,000 | Venture |
ARCH Venture Partners LAV Fund | undisclosed |
